Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

Background Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of moderate-to-severe AD in Europe, USA, Japan and several other countries. Objective To assess dupilumab eff...

Full description

Bibliographic Details
Main Authors: S. Barbarot, A. Wollenberg, J. I. Silverberg, M. Deleuran, G. Pellacani, J. C. Armario-Hita, Z. Chen, B. Shumel, L. Eckert, A. Gadkari, Y. Lu, A. B. Rossi
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Journal of Dermatological Treatment
Subjects:
adults
atopic dermatitis
dupilumab
scorad
Online Access:http://dx.doi.org/10.1080/09546634.2020.1750550

Internet

http://dx.doi.org/10.1080/09546634.2020.1750550

Similar Items